Baylor University

The SGLT2 inhibitor empagliflozin improved CV and renal outcomes in patients with HF with reduced ejection fraction, regardless of diabetes status, according to results of the EMPEROR-Reduced trial.

Boehringer Ingelheim and Eli Lilly and Co. announced that the SGLT2 inhibitor empagliflozin to treat patients with HF with reduced ejection fraction, with and without diabetes, met its primary endpoint in the phase 3 EMPEROR-Reduced trial.

A 3-year-old male living in Puerto Rico presented with progressive bilateral foot and lower extremity pain. He had been healthy until 4 months earlier, when he was diagnosed with influenza B. In addition to the common symptoms of influenza at that time, he also had the onset of pain in both feet. This pain continued, with a pattern of getting worse in the mornings, and reached a point where the patient refused to wear shoes. An orthopedic consultant failed to find a problem, and the patient was treated with pain medication, which had minimal effect. As his pain continued, he began having painful gingival swelling and erythema. His dentist referred him to a local hospital, where he was diagnosed with gingivitis and myositis, supported by an elevated CPK of 1760 and an ESR of 40, with a negative bone scan. The patient’s gingival edema worsened, with friable bleeding gums and ongoing leg pains, and he was taken to the regional medical center. Additional history revealed that he never had fever, night sweats or joint inflammation or swelling, but he did have a mild, transient rash, now resolved.

The Leukemia & Lymphoma Society awarded $13.8 million in new pediatric research grants designed to identify more effective and precise treatments for children with blood cancer.

More than half of patients with pancreatic adenocarcinoma showed clinical responses when treated with an investigational multiantigen-specific T-cell therapy, according to the results of an ongoing phase 1 clinical trial presented at the ACCR’s Immune Cell Therapies for Cancer conference in San Francisco.

Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a joint society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology.

Genetic sequencing of tumors among children with refractory cancer led to about a quarter of those tested being matched with therapies targeting their specific genetic alteration, according to results of a study scheduled for presentation at ASCO Annual Meeting.

ATLANTA — Adults and children with advanced HER2-positive sarcoma safely tolerated and derived clinical benefit from lymphodepletion chemotherapy followed by infusions of autologous HER2-targeted chimeric antigen receptor T cells, according to results of a phase 1 trial presented at American Association for Cancer Research Annual Meeting.

SAN ANTONIO — Completion of a lifestyle intervention program that focused on healthy habits appeared associated with weight loss and increased DFS among a cohort of early-stage breast cancer survivors, according to results of an interim analysis of the SUCCESS C study presented at San Antonio Breast Cancer Symposium.

Researchers at Keck School of Medicine of USC are leading a $26.5 million effort to conduct the first large-scale study of black men with prostate cancer.